Temozolomide for the treatment of recurrent supratentorial glioma: Results of a compassionate use program in Belgium

Journal of Neuro-Oncology

Volumn 70, Issue 1, 2004, Pages 37-48

  Everaert, Els ^a   Neyns, Bart ^b   Joosens, Eric ^c   Strauven, Theo ^c   Branle, Fabrice ^d   Menten, Johan ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c AZ Sint Augustinus Wilrijk ^*  (Belgium)

^d ERASME HOSPITAL   (Belgium)

Author keywords

Astrocytoma; Brain; Chemotherapy; Glioblastoma; Oligodendroglioma; Recurrent; Temozolomide; Tumor

Indexed keywords

GADOLINIUM; GRANULOCYTE COLONY STIMULATING FACTOR; NITROSOUREA; TEMOZOLOMIDE;

ADULT; AGED; ANAMNESIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTOMA; BELGIUM; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL OBSERVATION; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; REPRODUCIBILITY; RETROSPECTIVE STUDY; SEPTIC SHOCK; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BELGIUM; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SUPRATENTORIAL NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 4444306160     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NEON.0000040809.97943.c0     Document Type: Article

References (30)

1. Surawicz TS, McCarthy BJ, Kupelian V et al.: Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro-oncol 1: 14-25, 1999
2. DeAngelis LM: Brain tumors. N Engl J Med 344: 114-23, 2001
3. van den Bent M, Chinot OL, Cairncross JG: Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro-oncol 5: 128-138, 2003
4. Cairncross G, Macdonald D, Ludwin S et al.: Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12: 2013-2021, 1994
5. van den Bent MJ, Kros JM, Heimans JJ et al.: Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 51: 1140-1145, 1998
6. Soffietti R, Ruda R, Bradac GB et al.: PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43: 1066-1073, 1998
7. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018, 2002
8. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 19: 509-518, 2001
9. Tsang LL, Farmer PB, Gescher A et al.: Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother Pharmacol 26: 429-436, 1990
10. Wedge SR, Porteus JK, May BL et al.: Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. Br J Cancer 73: 482-490, 1996
11. Brada M, Judson I, Beale P et al.: Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81: 1022-1030, 1999
12. Quinn JA, Reardon DA, Friedman AH et al.: Phase II trial of temozolomide in patients with progressive lowgrade glioma. J Clin Oncol 21: 646-651, 2003
13. Brada M, Viviers L, Abson C et al.: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14: 1715-1721, 2003
14. Pace A, Vidiri A, Galie E et al.: Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 14: 1722-1726, 2003
15. Trent S, Kong A, Short SC et al.: Temozolomide as second-line chemotherapy for relapsed gliomas. J Neurooncol 57: 247-251, 2002
16. Newlands ES, O'Reilly SM, Glaser MG et al.: The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A: 2236-2241, 1996
17. Janinis J, Efstathiou E, Panopoulos C et al.: Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status. Med Oncol 17: 106-110, 2000
18. Yung WK, Albright RE, Olson J et al.: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588-593, 2000
19. Brada M, Hoang-Xuan K, Rampling R et al.: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12: 259-266, 2001
20. Bower M, Newlands ES, Bleehen NM et al.: Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40: 484-488, 1997
21. Yung WK, Prados MD, Yaya-Tur R et al.: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17: 2762-2771, 1999
22. Brandes AA, Ermani M, Basso U et al.: Temozolomide as a second-line systemic regimen in recurrent high-grade fglioma: a phase II study. Ann Oncol 12: 255-257, 2001
23. Osoba D, Brada M, Yung WK et al.: Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18: 1481-1491, 2000
24. Stupp R, Dietrich PY, Ostermann Kraljevic S et al.: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20: 1375-1382, 2002
25. Athanassiou H, Synodinou M, Maragoudakis E et al.: Temozolomide (TMZ) combined with radiotherapy (RT) versus radiotherapy (RT) alone in newly diagnosed glioblastoma, multiforme (GBM): a randomized phase III study. Eur Cancer Suppl 1: S95, 2003
26. Trippoli S, Pelagotti F, Messori A et al.: Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. Drugs RD4: 285-291, 2003
27. Macdonald DR, Cascino TL, Schold SC, Jr. et al.: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990
28. Simon R, Makuch RW: A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med 3: 35-44, 1984
29. Chang SM, Theodosopoulos P, Lamborn K et al.: Temozolomide in the treatment of recurrent malignant glioma. Cancer 100: 605-611, 2004
30. Gilbert MR, Friedman HS, Kuttesch JF et al.: A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncol 4: 261-267, 2002